{"prompt": "['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'PFS and os according to circulating tumor DNA at baseline (ctDNA positive vs.', 'negative)', 'Outcome in molecular subgroups', 'Trial design', 'This is an open-label, randomized, controlled, multicenter, phase III study with two', 'parallel arms. Patients with metastatic colorectal cancer after definite interventional', 'therapy of all lesions are randomized in a 2:1 fashion (favoring active therapy) to', 'investigate the efficacy, patient reported quality of life and safety of', 'mFOLFOXIRI/mFOLFOX-6 as additive treatment (Arm A) versus active follow-', 'up/surveillance (Arm B).', 'During the randomization process stratification will be performed according to the', 'following parameters:', 'number of treated metastases:', 'i) > 2 VS. 1-2', 'pretreatment with systemic therapy for metastatic colorectal cancer:', 'ii) yes VS. no', 'choice of potential therapy in the trial:', 'iii) fit for mFOLFOXIRI vs. fit for mFOLFOX-6', 'presence of at least one of the following unfavorable prognostic factor:', 'iv) peritoneal metastases resected/ known BRAF mutation/', 'synchronous metastases defined as evidence of metastases < 12', 'months vs. 12 months after first diagnosis vs. no unfavorable', 'prognostic factor', 'Treatment in Arm A is continued for a maximum of 12 cycles of 2 weeks interval (i.e.', 'appr. 24 weeks) or until occurrence of progression evaluated by the investigator or', 'unacceptable toxicity.', 'Patients are followed up with regard to survival and if applicable subsequent anti-', 'cancer treatments until death or for at least 5 years after randomization, whichever', 'date is earlier.', 'The trial design is displayed in the following figure:', 'P.RT', 'Post-Resection Therapy in patients with metastatic colorectal cancer', 'Fire-9 I AIO 0418', 'Study design', 'Primary endpoint: progression-free survival (PFS)', 'mFOLFOXIRI q2w (up to 6 months)', 'Relapse', 'adjusted treatment duration up to total months', 'mCRC, ECOG 0-1', 'oxaliplatin-based therapy including pre-operative regimens', 'Structured', 'specimen', '2/3', 'mFOLFOX6 q2w (up to 6 months)', 'Follow-up', 'After definitive', 'adjusted treatment duration up to total of months', 'treatment of', 'oxaliplatin- based therapy including pre -operative regimens', 'any metastases', '(incl surgery stereotactic', 'Relapse', 'radiation. ablative techniques)', '13', 'Structured Follow-up', 'specimen', 'Stratification', 'number treated metastases', '(>2 vs. 1-2)', '2. protreatment with systemic thorapy', 'metastatic colorectal cancer', 'yes vs.', '3. choice of potential therapy  the trial', '(fit for fit for FOLFOX)', '4.', 'presence least bad prognostic', 'factor (peritoneal metastases resected/', 'Biomarkers', 'Biomarkers', 'known BRAF mutation/ synchronous', 'metastases defined evidence', 'Tumor samples', 'Tumor samples', 'metastases <12 months >12 months', 'after first diagnosis) vs no bad prognostic', 'Blood samples', 'Blood samples', 'factor)', 'Confidential', 'Page 14 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'Inclusion', '1.', \"Patient's signed informed consent.\", 'criteria', '2.', \"Patient's age >18 years at the time of signing the informed consent.\", '3.', 'Histologically confirmed adenocarcinoma of the colon or rectum.', '4. Resected (R0 or R1) and/or effectively treated metastases (all techniques', 'allowed) of colorectal cancer within 3-10 weeks before randomization AND', 'resected primary tumor (synchronous or metachronous).', '5.', 'Absence of significant active wound healing complications (if applicable) prior to', 'randomization. Resolved wound healing complications after resection/ablation', 'are acceptable for inclusion into the trial.', '6.', 'No radiographic evidence of active metastatic disease at study entry in a CT', 'and/or MRI scan not older than 8 weeks. Pre-surgery/ablation images are', 'eligible for the study if all lesions have been addressed in the interval.', '7.', 'ECOG performance status 0-2.', '8. Adequate bone marrow, hepatic and renal organ function, defined by the', 'following laboratory test results:', 'Absolute neutrophil count 1.5 X 10%/L (1500/L)', 'Hemoglobin 80 g/L (8 g/dL)', 'Platelet count 100 x10%/L (100000/L) without transfusion', 'Total serum bilirubin of < 1.5 X upper limit of normal (ULN)', 'Aspartate aminotransferase (AST/GOT) < 3.0 x ULN.', 'Calculated glomerular filtration rate (GFR) according to Cockcroft-Gault', 'formula or according to MDRD 50 mL/min or serum creatinine 1.5 X ULN', '9.', 'Patients without anticoagulation need to present with an INR < 1.5 X ULN and', 'PTT < 1.5 X ULN. Patient with prophylactic or therapeutic anticoagulation are', 'allowed into the trial.', '10. Proficient fluorouracil metabolism as defined:', 'a) Prior treatment with 5-FU or capecitabine without unusal toxicity', 'or', 'b) If tested, normal DPD deficiency test according to the standard of the study', 'site', 'or', 'c)', 'If tested, in patients with DPD deficiency test with a CPIC activity score of', '1.0-1.5 fluoropyrimidine dosage should be reduced by 50%', '11. For women of childbearing potential (WOCBP): negative pregnancy test within', '14 days before randomization and agreement to remain abstinent (refrain from', 'heterosexual intercourse) or use contraceptive methods with a failure rate of', '< 1% per year during the treatment period and for at least 6 months after the last', 'dose of study treatment.', 'A woman is considered to be of childbearing potential if she is post-menarcheal,', 'has not reached a postmenopausal state ( 12 continuous months of', 'amenorrhea with no identified cause other than menopause), and has not', 'undergone surgical sterilization (removal of ovaries and/or uterus). Examples of', 'contraceptive methods with a failure rate of < 1% per year include bilateral tubal', \"ligation, male partner's sterilization, hormonal contraceptives that inhibit\", 'ovulation, hormone-releasing intrauterine devices, and copper intrauterine', 'devices.', 'For men: With female partners of childbearing potential, men must remain', 'abstinent or use a condom plus an additional contraceptive method that together', 'result in a failure rate of < 1% per year during the treatment period and for 6', 'Confidential', 'Page 15 of 79']\n\n###\n\n", "completion": "END"}